Semaglutide
Controls blood sugar and manages weight by mimicking GLP-1
GLP-1 agonism recalibrates appetite and insulin.
Activates the GLP-1 receptor on pancreatic β-cells and in the brainstem, boosting glucose-dependent insulin and telling the hypothalamus you're full.
- Slows gastric emptying — food sits longer, hunger fades sooner.
- Lowers glucagon when blood sugar is already normal.
- Also approved for reducing major cardiovascular events in T2D.
Semaglutide mimics GLP-1, a gut hormone released after eating. It directly signals the brain's appetite center to reduce hunger, slows gastric emptying, and stabilizes blood sugar. The outcome: you eat smaller portions without feeling restricted. Backed by extensive clinical trials and sold as Ozempic or Wegovy.
How long it stays, how it leaves.
Fixed dosing — not weight-adjusted. The calculator handles reconstitution math for common vial sizes so you inject the right volume every time.
Three tiers, three goals.
This is just the starting dose — standard titration goes: 250 mcg (wks 1-4) → 500 mcg (wks 5-8) → 1 mg (wks 9-12) → 1.7 mg (wks 13-16) → 2.4 mg max
Only increase by 250–500 mcg every 4 weeks if nausea is tolerable
FDA-approved max for weight loss (Wegovy) is 2.4mg/week — most people never need to go this high
What people actually report.
- Nausea (very common — 44%)
- Vomiting
- Diarrhea or constipation
- Stomach pain
- Muscle loss if you don't exercise and eat enough protein
Before you start.
- FDA-approved as Ozempic (diabetes) and Wegovy (weight loss) — one of the most studied peptides in existence
- Never skip titration steps — jumping up in dose too fast is why people quit from nausea
- Standard titration: 250 mcg → 500 mcg → 1 mg → 1.7 mg → 2.4 mg, moving up only every 4 weeks
- See a doctor immediately for severe stomach pain (pancreatitis risk)
- Don't use if you have a personal or family history of thyroid cancer
- Lift weights and eat 0.7–1g of protein per lb of body weight to prevent muscle loss